Delicate biogenerics dance

Following contentious discussions last week among senior managers of several member companies, the Biotechnology Industry Organization is finalizing the wording of a letter to FDA outlining its position about patent and trade secret issues associated with follow-on biologics.

The letter will endorse principles articulated by Genentech Inc. in a Citizen Petition filed in April, including concepts that overlap with a similar petition filed by Pfizer Inc. in May, BIO President Carl Feldbaum told BioCentury...